MedWatch

Ambu downgrades financial expectations

After trading closed on Tuesday, Ambu lowered its expectations for its financial year of 2020/21 due to delayed component deliveries in its Core business.

Photo: Ambu/PR

Medtech company Ambu has downgraded its financial guidance for its accounting year of 2020/21 after sales and income for its Core business were affected by the challenging global shipping conditions.

Ambu announced in a stock exchange notification that it now expects total organic growth for the year of 16 percent, compared to a previous estimate of 17 percent.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs